Intersect ENT Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT or view top-rated stocks.

Wall Street analysts have given Intersect ENT a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intersect ENT wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Intersect ENT is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Intersect ENT.

Intersect ENT, Inc. (NASDAQ:XENT) announced its earnings results on Monday, May, 10th. The medical equipment provider reported ($0.51) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.09. The medical equipment provider had revenue of $24.30 million for the quarter, compared to the consensus estimate of $23.54 million. Intersect ENT had a negative net margin of 87.96% and a negative trailing twelve-month return on equity of 91.97%. Intersect ENT's quarterly revenue was up 22.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.54) EPS.
View Intersect ENT's earnings history.

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XENT shares have decreased by 25.1% and is now trading at $16.11.
View which stocks have been most impacted by COVID-19.

Intersect ENT updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $117 million-121 million, compared to the consensus revenue estimate of $119.41 million.

7 Wall Street analysts have issued twelve-month price objectives for Intersect ENT's shares. Their forecasts range from $19.00 to $32.00. On average, they anticipate Intersect ENT's stock price to reach $25.00 in the next year. This suggests a possible upside of 55.2% from the stock's current price.
View analysts' price targets for Intersect ENT or view top-rated stocks among Wall Street analysts.

7 employees have rated Intersect ENT CEO Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Intersect ENT include iRhythm Technologies (IRTC), Inovio Pharmaceuticals (INO), Silk Road Medical (SILK), Luminex (LMNX), Cardiovascular Systems (CSII), Pulmonx (LUNG), Alphatec (ATEC), Treace Medical Concepts (TMCI), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), OrthoPediatrics (KIDS), CryoLife (CRY), Atrion (ATRI), Tactile Systems Technology (TCMD) and SI-BONE (SIBN).
View all of XENT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG), Air Transport Services Group (ATSG), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and AbbVie (ABBV).

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Intersect ENT's stock is owned by a number of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (11.37%), BlackRock Inc. (8.98%), First Light Asset Management LLC (6.15%), Great Point Partners LLC (4.02%), Rock Springs Capital Management LP (3.26%) and Neuberger Berman Group LLC (2.98%). Company insiders that own Intersect ENT stock include Richard A Meier, Robert H Binney, Jr and Thomas A West.
View institutional ownership trends for Intersect ENT.

XENT stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Jennison Associates LLC, D. E. Shaw & Co. Inc., Neuberger Berman Group LLC, Bank of New York Mellon Corp, Northern Trust Corp, Nuveen Asset Management LLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Intersect ENT or view top insider-selling stocks.

XENT stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Artisan Partners Limited Partnership, Rock Springs Capital Management LP, Polar Asset Management Partners Inc., BlackRock Inc., Eversept Partners LP, Altium Capital Management LP, and Geode Capital Management LLC. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT or or view top insider-buying stocks.

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XENT stock can currently be purchased for approximately $16.11.

Intersect ENT has a market capitalization of $533.90 million and generates $80.55 million in revenue each year. The medical equipment provider earns $-72,320,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

Intersect ENT employs 406 workers across the globe.

The official website for Intersect ENT is www.intersectent.com.

Intersect ENT is headquartered at 1555 ADAMS DRIVE, MENLO PARK CA, 94025.

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]